TY - JOUR
T1 - Pathological review of cardiac amyloidosis using autopsy cases in a single Japanese institution
AU - Tateishi, Yuki
AU - Yamada, Yuichi
AU - Katsuki, Masato
AU - Nagata, Takuya
AU - Yamamoto, Hidetaka
AU - Kouhashi, Kenichi
AU - Koga, Yutaka
AU - Hashisako, Mikiko
AU - Kiyozawa, Daisuke
AU - Mori, Taro
AU - Kuboyama, Yusuke
AU - Kakinokizono, Ayumi
AU - Miyazaki, Yoshiko
AU - Yamaguchi, Aina
AU - Tsutsui, Hiroyuki
AU - Ninomiya, Toshiharu
AU - Naiki, Hironobu
AU - Oda, Yoshinao
N1 - Funding Information:
This study was supported by a Japan Society for Promotion of Science ( JSPS ) KAKEN Grant (No. 19K16559 ) and by funds from the Scholarship Program of the Takeda Science Foundation .
Publisher Copyright:
© 2021 Elsevier GmbH
PY - 2021/11
Y1 - 2021/11
N2 - Aim: Amyloidosis is a systemic or localized disease of protein deposition characterized by amorphous eosinophilic morphology and positivity of Congo Red staining. The typing of amyloidosis is becoming increasingly important because therapeutic agents for each amyloidosis type have been developed. Herein, the authors review the autopsy cases at an institution to reveal the putative Japanese characteristics of each amyloidosis type and evaluate the clinicopathological significance of each type. Materials and methods: A total of 131 autopsy cases of systemic and localized amyloidosis were retrieved for classification by immunohistochemistry. Immunohistochemistry for transthyretin, amyloid A (AA), immunoglobulin light-chain kappa and lambda, and β2-microglobulin was performed for all cases. Results: The 131 amyloidosis cases were classified as follows: 71 cases (54.2%) of transthyretin amyloidosis, 32 cases (24.4%) of AA amyloidosis, 8 cases (6.1%) of light-chain amyloidosis, and 5 cases (3.8%) of β2-microglobulin amyloidosis, along with 15 equivocal cases (11.5%). All cases showed myocardial involvement of amyloidosis. Histopathologically, the transthyretin type was significantly associated with the interstitial and nodular patterns, and with the absence of the perivascular and endocardial patterns. The AA type was significantly associated with the perivascular and endocardial patterns, and with the absence of the nodular pattern. Conclusion: The authors revealed the putative characteristics of cardiac amyloidosis in Japan by using autopsy cases. About 90% of amyloidosis cases were successfully classified using only commercially available antibodies.
AB - Aim: Amyloidosis is a systemic or localized disease of protein deposition characterized by amorphous eosinophilic morphology and positivity of Congo Red staining. The typing of amyloidosis is becoming increasingly important because therapeutic agents for each amyloidosis type have been developed. Herein, the authors review the autopsy cases at an institution to reveal the putative Japanese characteristics of each amyloidosis type and evaluate the clinicopathological significance of each type. Materials and methods: A total of 131 autopsy cases of systemic and localized amyloidosis were retrieved for classification by immunohistochemistry. Immunohistochemistry for transthyretin, amyloid A (AA), immunoglobulin light-chain kappa and lambda, and β2-microglobulin was performed for all cases. Results: The 131 amyloidosis cases were classified as follows: 71 cases (54.2%) of transthyretin amyloidosis, 32 cases (24.4%) of AA amyloidosis, 8 cases (6.1%) of light-chain amyloidosis, and 5 cases (3.8%) of β2-microglobulin amyloidosis, along with 15 equivocal cases (11.5%). All cases showed myocardial involvement of amyloidosis. Histopathologically, the transthyretin type was significantly associated with the interstitial and nodular patterns, and with the absence of the perivascular and endocardial patterns. The AA type was significantly associated with the perivascular and endocardial patterns, and with the absence of the nodular pattern. Conclusion: The authors revealed the putative characteristics of cardiac amyloidosis in Japan by using autopsy cases. About 90% of amyloidosis cases were successfully classified using only commercially available antibodies.
UR - http://www.scopus.com/inward/record.url?scp=85116891886&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85116891886&partnerID=8YFLogxK
U2 - 10.1016/j.prp.2021.153635
DO - 10.1016/j.prp.2021.153635
M3 - Article
C2 - 34653913
AN - SCOPUS:85116891886
SN - 0344-0338
VL - 227
JO - Pathology Research and Practice
JF - Pathology Research and Practice
M1 - 153635
ER -